U.S. authorizes second COVID booster for Americans 50 and older
Send a link to a friend
[March 30, 2022]
By Michael Erman and Manojna Maddipatla
(Reuters) - U.S. health officials on
Tuesday authorized a second COVID-19 booster dose of the two most
commonly used COVID-19 vaccines for people age 50 and older, citing data
showing waning immunity and the risks posed by Omicron variants of the
virus.
The U.S. Food and Drug Administration agency said the new boosters - a
fourth round of shots for most vaccine recipients - of the Pfizer Inc/BioNTech
SE and Moderna Inc vaccines are to be administered at least four months
after the previous dose. They are intended to offer more protection
against severe disease and hospitalization.
The FDA also authorized a second booster dose of the vaccines for
younger people with compromised immune systems - those aged 12 and older
for the Pfizer/BioNTech shot and 18 and older for Moderna's.
The U.S. Centers for Disease Control and Prevention (CDC) backed the
FDA's authorization, recommending the additional shot, particularly for
older people and those with underlying medical conditions that put them
at higher risk.
The decision to offer second boosters in the United States comes as some
scientists have raised concern about the highly contagious and newly
predominant BA.2 Omicron subvariant, which has driven up COVID-19 cases
in other countries.
"If it were my relatives, I would be sending them out to do this," top
FDA official Dr. Peter Marks said during a news conference of getting
booster shots. "COVID-19 has had a really disproportional adverse effect
on people 65 years of age and older and those with comorbidities."
COVID cases in the United States have dropped sharply since a record
surge in January, but have seen a small uptick over the past week,
according to CDC data.
BROADER BOOSTER CAMPAIGN MAY BE NEEDED
Marks said the FDA will soon weigh the benefits of authorizing another
round of boosters - perhaps specifically targeted to combat new variants
of concern - to a broader population after the summer.
"There may be a need for people to get an additional booster in the fall
along with a more general booster campaign, if that takes place, because
we may need to shift over to a different variant coverage," he said.
[to top of second column]
|
A man receives a booster dose of Pfizer's coronavirus disease
(COVID-19) vaccine at a vaccination centre in Brussels, Belgium,
January 5, 2022. REUTERS/Yves Herman
The FDA said it looked at data from
a relatively small, ongoing clinical trial in Israel to help make
its decision. In addition, safety data from more than 700,000 people
who received second boosters in Israel revealed no new concerns, the
agency said.
Scientists and officials have debated for months if and when an
additional booster shot would be needed as they parsed data on how
long protection from the vaccines and boosters would last.
"It's not clear that now is the right time for
people to get a fourth dose," Dr. William Moss, executive director
of the International Vaccine Access Center at the Johns Hopkins
Bloomberg School of Public Health said.
If there is a surge in cases in late fall or early winter, as is
typical for respiratory viruses and influenza, an additional boost
may then be needed, he said. The body's neutralizing antibodies
spurred on by a fourth booster given now may decline in just a few
months, he said.
It is also unclear whether young, healthy people will need a fourth
shot. The study of Israeli healthcare workers cited by the FDA
suggested that the fourth dose added little additional protection in
the age group.
Biden administration officials have said that the U.S. government
currently has enough doses of the vaccines to meet the demand for
another round of booster shots in older Americans, even as funding
for the U.S. pandemic response has all but run out.
They say that unless Congress approves more spending, the government
will not be likely to be able to be pay for future inoculations, if
they are needed, particularly if the vaccines need to be redesigned
to target new variants.
Around two-thirds of fully vaccinated Americans over the age of 65
and just over half of people between the age of 50 and 64 have
gotten their first booster dose so far.
(Reporting by Michael Erman in New Jersey, Manojna Maddipatla and
Leroy Leo in Bengaluru, Additional reporting by Ahmed Aboulenein in
Washington; Editing by Bill Berkrot)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|